Evogene (EVGN) Gross Profit (2012 - 2026)
Evogene (EVGN) posted Gross Profit of $204000.0 for Q1 2026, up 110.36% sequentially from -$2.0 million in Q4 2025, and down 75.3% YoY from $826000.0 in Q1 2025.
Evogene (EVGN) Gross Profit (2012 - 2026) Analysis & Trends
Evogene has reported Gross Profit for 15 years, with the latest figure at $204000.0 in Q1 2026.
- Quarterly Gross Profit fell 75.3% year-over-year to $204000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$863000.0 (down 132.64% YoY) and the FY2025 annual result came in at -$241000.0, down 107.54% from the prior year.
- Gross Profit advanced to $204000.0 in Q1 2026 per EVGN's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Gross Profit peaked at $3.9 million in Q1 2024 and troughed at -$2.0 million in Q4 2025.
- A 5-year average of $610294.1 and a median of $296000.0 in 2022 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2024 and 2025: Gross Profit jumped 1116.3% in 2024, then slumped 331.49% in 2025.
- Over 5 years, Gross Profit stood at $296000.0 in 2022, then tumbled by 39.19% to $180000.0 in 2023, then surged by 372.78% to $851000.0 in 2024, then tumbled by 331.49% to -$2.0 million in 2025, then soared by 110.36% to $204000.0 in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $204000.0, -$2.0 million, and $155000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | -1.97 Mn |
| Dec 31, 2025 | -1.97 Mn |
| Sep 30, 2025 | 155,000.00 |
| Sep 30, 2025 | 155,000.00 |
| Jun 30, 2025 | 748,000.00 |
| Jun 30, 2025 | 748,000.00 |
| Mar 31, 2025 | 826,000.00 |
| Mar 31, 2025 | 826,000.00 |
| Dec 31, 2024 | 851,000.00 |
| Dec 31, 2024 | 851,000.00 |
| Sep 30, 2024 | 698,000.00 |
| Sep 30, 2024 | 698,000.00 |
| Jun 30, 2024 | 269,000.00 |
| Jun 30, 2024 | 269,000.00 |
| Mar 31, 2024 | 3.88 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Dec 31, 2023 | 180,000.00 |
| Dec 31, 2023 | 180,000.00 |